Semaglutide 7.2 mg (STEP UP Trial): Does Higher-Dose Wegovy Work Better?

For four years, 2.4 mg was the ceiling for weight-loss semaglutide. The STEP UP trial pushed past it. Novo Nordisk tested a 7.2 mg dose — three times the standard Wegovy strength — to see if more drug means more weight lost. The answer is yes, but with real trade-offs. Here is what the data show, what it does not settle, and how the higher dose stacks up against tirzepatide.

Quick Answer

STEP UP tested semaglutide 7.2 mg against the standard 2.4 mg Wegovy dose.
The 7.2 mg arm lost 18.7% of body weight at 72 weeks vs 15.6%.
Side effects rose too: 71% had gut issues and 23% reported nerve tingling.
It is not FDA-approved yet; regulatory filings began in late 2025.

What is semaglutide 7.2 mg?

Semaglutide is the GLP-1 medication sold as Wegovy for weight loss and Ozempic for type 2 diabetes. The current top weight-loss dose is 2.4 mg once weekly. Semaglutide 7.2 mg is an investigational higher dose — the same molecule, roughly three times the strength.

Why test a higher dose at all?

Weight loss with GLP-1 drugs is dose-dependent up to a point. Earlier work showed bigger doses tend to drive bigger loss, until side effects or a biological ceiling take over. The question STEP UP set out to answer was simple. Does going above 2.4 mg buy meaningful extra weight loss, or just extra nausea?

Is 7.2 mg a new drug?

No. It is the same semaglutide, delivered at a higher weekly amount. That matters for safety review. Regulators already have years of data on semaglutide's mechanism, so the main open question is what the extra dose does to the balance of benefit and harm.

Is this related to the oral pill?

Not directly. The 7.2 mg dose in STEP UP was injectable, given once a week under the skin. Oral semaglutide for obesity is a separate program. If you want the pill-versus-shot picture, see our oral vs injectable GLP-1 breakdown.

What did the STEP UP trial actually find?

STEP UP was a randomized, double-blind, phase 3b trial in 1,407 adults with obesity and without diabetes, published in The Lancet Diabetes & Endocrinology in 2025 (STEP UP, 2025). Participants were assigned to semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo, each once weekly for 72 weeks alongside lifestyle support.

The headline result: the 7.2 mg dose beat both the standard dose and placebo. Here are the core numbers.

Arm	Participants	Mean weight change at 72 weeks
Semaglutide 7.2 mg	1,005	−18.7%
Semaglutide 2.4 mg	201	−15.6%
Placebo	201	−3.9%

Source: STEP UP, 2025. The −18.7% figure uses the treatment-policy estimand, which counts everyone regardless of whether they stayed on the drug. Among people who stayed on treatment, average loss reached about 20.7%.

That estimand gap is worth understanding, because the two numbers answer different questions. The treatment-policy figure reflects real-world messiness — people who quit early, missed doses, or dropped out are still counted. The on-treatment figure reflects the drug's biological potential in people who actually take it as intended. Neither is "the" right answer; they bracket what you might expect. When you see one trial quoted at 18.7% and another at 20.7% for the same arm, this is usually why.

How many people hit the big weight-loss targets?

The higher dose moved people into deeper weight-loss territory. Compared with placebo, the odds of reaching a 20% or greater reduction were dramatically higher on 7.2 mg. Roughly a third of 7.2 mg users — more than 30% — reached at least 25% body-weight loss, a threshold that starts to rival what bariatric surgery delivers.

Was the extra weight loss statistically real?

Yes. The 7.2 mg dose was superior to both 2.4 mg and placebo on the trial's primary endpoints, with wide confidence intervals favoring the high dose for the 20% and 25% loss thresholds. This was a superiority trial, so beating the active 2.4 mg comparator was the point, not a bonus.

How does 7.2 mg compare to standard 2.4 mg Wegovy?

The gap between the two doses was about 3 percentage points of body weight — 18.7% vs 15.6%. That is real but not enormous. For a 200-pound person, it is the difference between losing roughly 31 pounds and roughly 37 pounds.

Measure	7.2 mg	2.4 mg
Mean weight loss (72 wk)	−18.7%	−15.6%
Gut side effects	70.8%	61.2%
Nerve-sensation events	22.9%	6.0%

Source: STEP UP, 2025. The extra 3 points of weight loss came bundled with more side effects, which is the central trade-off patients and clinicians will weigh.

Is the standard 2.4 mg dose now obsolete?

Not at all. The 2.4 mg dose already produces strong, durable loss, and it did so again here. For many people, the standard dose delivers most of the benefit with a gentler side-effect load. A higher ceiling gives clinicians another gear, not a reason to abandon the current one. Our Wegovy dose guide covers how the existing strengths are used.

Does more semaglutide mean more side effects?

Broadly, yes — though the drug stayed tolerable for most people. Gastrointestinal complaints were the most common issue, as they are across every GLP-1 dose.

Adverse event	7.2 mg	2.4 mg	Placebo
Any GI side effect	70.8%	61.2%	42.8%
Dysaesthesia (nerve tingling)	22.9%	6.0%	0.5%

Source: STEP UP, 2025. Most GI events were mild to moderate — nausea, constipation, diarrhea — and eased with time. The safety profile was consistent with what semaglutide's label already describes.

What is dysaesthesia and should it worry me?

Dysaesthesia is an abnormal skin sensation — tingling, prickling, or a mild burning feeling. It jumped sharply at the 7.2 mg dose, hitting nearly one in four participants versus one in sixteen on 2.4 mg. This was a newer signal that stood out in the high-dose arm and deserves honest attention.

The events were generally not serious in the trial. Still, a fourfold rise over the standard dose is exactly the kind of finding regulators scrutinize before approving a higher strength. If a higher dose reaches the market, expect this to be tracked closely.

Did more people quit the drug on the high dose?

Some did. Higher doses of any GLP-1 tend to push more people to stop over side effects, and slow titration is the usual defense. Managing nausea early is often what keeps people on treatment long enough to benefit — our nausea management guide walks through the evidence-based tactics.

Dose escalation: how would 7.2 mg be titrated?

GLP-1 medications are started low and stepped up slowly to limit nausea. The approved Wegovy ladder climbs to 2.4 mg over 16 weeks. STEP UP kept climbing past that point to reach 7.2 mg, using an extended titration.

Week	Standard Wegovy dose
1–4	0.25 mg
5–8	0.5 mg
9–12	1.0 mg
13–16	1.7 mg
17+	2.4 mg (maintenance)

Source: FDA-approved Wegovy labeling (Drugs@FDA). To reach 7.2 mg, STEP UP continued stepping the dose upward beyond 2.4 mg over additional weeks. The exact high-dose schedule would be set by the label if and when 7.2 mg is approved.

Why not just jump straight to the top dose?

Because side effects track how fast you climb, not just where you land. Escalating slowly gives the gut time to adapt and keeps people from quitting in the first month. Our semaglutide titration guide explains why patience beats speed here.

Could a faster or slower ladder change tolerability?

Possibly. Titration speed is an active research question across GLP-1 drugs, and the right pace may differ by person. STEP UP used a structured, gradual climb, which is the conservative approach and the one most likely to make it into practice.

Semaglutide 7.2 mg vs tirzepatide: does higher dose close the gap?

This is the question the 7.2 mg data cannot dodge. In the head-to-head SURMOUNT-5 trial, tirzepatide beat standard-dose semaglutide decisively — 20.2% vs 13.7% weight loss at 72 weeks (SURMOUNT-5, 2025).

Drug / dose	Trial	Weight loss (72 wk)
Tirzepatide (max dose)	SURMOUNT-5	−20.2%
Semaglutide 7.2 mg	STEP UP	−18.7%
Semaglutide 2.4 mg	STEP UP	−15.6%

These figures come from separate trials, so this is not a fair head-to-head — populations, estimands, and designs differ. But the pattern is telling. Higher-dose semaglutide narrows the gap with tirzepatide without clearly erasing it.

Why can't we just compare the numbers directly?

Because cross-trial comparison is a statistical trap. STEP UP and SURMOUNT-5 enrolled different people, used different estimands, and were run separately. The only clean answer would be a trial pitting semaglutide 7.2 mg directly against tirzepatide, which has not been done.

Does tirzepatide still look like the stronger option?

On the current evidence, tirzepatide remains the more potent single agent for weight loss, backed by a direct head-to-head win. The 7.2 mg data make semaglutide more competitive, not clearly superior. For the direct comparison, see our semaglutide vs tirzepatide head-to-head.

Who might benefit from 7.2 mg?

The higher dose is most relevant to people who need more weight loss than the standard dose delivers. Think of someone who has plateaued on 2.4 mg but still has a meaningful amount to lose, or someone with a higher starting weight and larger goals.

It is not a first-line starting point. Everyone would still begin low and titrate up, and most people would land on the standard dose first. The high dose is a next gear, reserved for those who tolerate semaglutide well and need more from it.

What if I have already plateaued on 2.4 mg?

A weight-loss stall does not automatically mean you need a higher dose. Plateaus often reflect a new metabolic set point rather than an under-dose. Our plateau guide covers what actually drives stalls before you reach for more medication.

Is a higher dose right for people who can't tolerate 2.4 mg?

No. If the standard dose already causes hard-to-manage nausea, a stronger dose is the wrong direction. Higher strength raised GI events in STEP UP, so poor tolerance at 2.4 mg is a reason to look at alternatives, not to climb.

What STEP UP does not tell us

A single trial, however large, leaves gaps. STEP UP measured 72 weeks in adults with obesity and without diabetes. It does not speak to everyone or every outcome.

We do not yet know how 7.2 mg performs over many years, whether the extra weight loss translates into fewer heart attacks or strokes, or how it behaves in people with diabetes. We also do not have a direct trial against tirzepatide. Those are open questions, not settled facts.

Does more weight loss mean better health outcomes here?

STEP UP measured weight, not heart attacks or deaths. More weight loss usually tracks with better cardiometabolic markers, but that link has to be proven, not assumed. The SELECT trial showed semaglutide 2.4 mg cut major cardiac events by about 20% (SELECT, 2023) — whether 7.2 mg adds to that is untested.

How durable is the 7.2 mg loss?

Unknown beyond 72 weeks. Two-year data on standard-dose semaglutide showed loss was largely maintained on continued treatment (STEP 5, 2022). Whether the high dose holds up the same way over multiple years has not been tested.

When will semaglutide 7.2 mg be available?

Not immediately. STEP UP is the pivotal efficacy trial, and Novo Nordisk signaled it would seek label updates in markets where 2.4 mg is already approved, starting in the second half of 2025. Regulatory review takes time.

Approval is not guaranteed, and timelines vary by country. The dysaesthesia signal and the modest size of the extra weight loss are the kinds of details reviewers weigh against the benefit. Until a regulator clears it, 7.2 mg is investigational and not something to seek from compounders or gray-market sellers.

Should I ask my doctor to prescribe it now?

No. It is not approved, and prescribing an unapproved dose off-label carries real risk. The safe move is to optimize the approved doses with your clinician and watch for official regulatory decisions.

Is compounded high-dose semaglutide the same thing?

No, and this is important. Compounded products at non-standard strengths are not the studied STEP UP formulation and carry their own safety and legality concerns. A high number on a compounder's vial is not evidence-backed dosing.

How does higher-dose semaglutide fit the broader evidence?

STEP UP is the newest chapter in a long, consistent story. The STEP program has repeatedly shown that semaglutide drives substantial, durable weight loss across settings.

Trial	Dose / comparison	Key weight-loss result
STEP 1	2.4 mg vs placebo	−14.9% at 68 weeks
STEP 3	2.4 mg + intensive therapy	−16.0% at 68 weeks
STEP 8	2.4 mg vs liraglutide	−15.8% vs −6.4%
STEP UP	7.2 mg vs 2.4 mg	−18.7% vs −15.6%

Sources: STEP 1, 2021; STEP 3, 2021; STEP 8, 2022; STEP UP, 2025. Read together, they show a clear dose-response: more semaglutide, more weight lost, up to a point where side effects start to bite.

Where does the 7.2 mg dose sit in that arc?

At the top of it. STEP UP is the deepest weight loss the semaglutide program has produced, edging past every prior standard-dose result. It confirms the dose-response holds even at three times the current strength.

How does 7.2 mg fit the next-generation GLP-1 race?

STEP UP arrives in a crowded field. Semaglutide 7.2 mg is Novo Nordisk defending its position while newer, more potent agents move through trials. The competitive picture shapes how much the higher dose matters.

Tirzepatide already sets a high bar with its direct SURMOUNT-5 win. Behind it sit even more aggressive candidates — retatrutide, a triple agonist, and CagriSema, a semaglutide-plus-cagrilintide combination — both targeting weight loss that could exceed 20%. Against that backdrop, a 3-point bump from a higher semaglutide dose is a meaningful but incremental move.

Is a stronger semaglutide dose enough to keep pace?

It helps, but it may not be decisive. The 7.2 mg dose keeps semaglutide competitive with tirzepatide and buys Novo Nordisk time while its combination and next-generation programs mature. For where all of this is heading, see our next-gen GLP-1 pipeline landscape.

Why release a higher dose instead of waiting for newer drugs?

Because semaglutide is proven, familiar, and already manufactured at scale. A higher dose reuses years of safety data and existing supply chains, so it can reach patients far faster than a brand-new molecule. It is a pragmatic way to raise the ceiling without starting from zero.

Maintenance and weight regain: does a higher dose change the exit problem?

Higher doses do not fix the core challenge of GLP-1 therapy — weight tends to return when you stop. When semaglutide was withdrawn in one trial, participants regained a large share of lost weight and saw cardiometabolic gains reverse (STEP 1 extension, 2022). Continued treatment, by contrast, preserved the loss (STEP 4, 2021).

A stronger dose likely means a longer way to fall if treatment stops abruptly. That makes a maintenance plan more important, not less. Our maintenance-dose guide covers how people think about staying at goal weight.

Would people step down from 7.2 mg to a lower maintenance dose?

That is plausible but untested for this dose. The same maintenance logic applies to tirzepatide, where continued treatment preserved loss (SURMOUNT-4, 2024). Whether a 7.2-to-2.4 mg step-down holds weight off is a question future trials will need to answer.

Frequently Asked Questions

How much more weight do you lose on semaglutide 7.2 mg vs 2.4 mg?

About 3 percentage points more. In STEP UP, the 7.2 mg arm lost 18.7% of body weight versus 15.6% on 2.4 mg at 72 weeks. For a 200-pound person, that is roughly an extra 6 pounds.

Is semaglutide 7.2 mg FDA-approved?

No. As of 2026 it remains investigational. STEP UP is the pivotal trial, and regulatory filings began in late 2025, but no regulator has approved the 7.2 mg dose for weight loss.

Is 7.2 mg semaglutide as effective as tirzepatide?

Not clearly. Tirzepatide beat standard-dose semaglutide directly in SURMOUNT-5 (20.2% vs 13.7%). The 7.2 mg dose narrows that gap in separate trials but has never been tested head-to-head against tirzepatide.

What are the main side effects of semaglutide 7.2 mg?

Mostly gastrointestinal — nausea, constipation, and diarrhea affected about 71% of users. A newer signal, dysaesthesia or nerve tingling, appeared in roughly 23%, far more than on the standard dose.

Can I get semaglutide 7.2 mg from a compounding pharmacy?

You should not treat compounded high-dose products as equivalent. They are not the studied STEP UP formulation, are not FDA-approved at that strength, and carry safety and legality concerns. Talk to a licensed clinician instead.

Medical Disclaimer

This article is for general information only and is not medical advice. Semaglutide 7.2 mg is investigational and not FDA-approved for weight loss as of 2026. GLP-1 medications carry risks and are not appropriate for everyone, including people with a personal or family history of medullary thyroid carcinoma or MEN 2, and those who are pregnant. Do not start, stop, or change any medication or dose based on this article. Always consult a qualified healthcare provider about your individual situation. For FDA safety information on semaglutide medications, see the FDA's semaglutide page.

— The GLP-1 Daily Team